BPC-157 and TB-500: what the research actually shows

The Supptide teamPublished Nov 3, 2026 Reviewed Nov 10, 2026

Educational; not medical advice. Supptide doesn't sell peptides and isn't affiliated with any drug maker or peptide seller.

Educational; not medical advice. Supptide doesn't sell, source or recommend either compound, and this article gives no dosing. Last reviewed 27 October 2026.

BPC-157 and TB-500 are two of the most talked-about peptides for injury recovery. Here's what the published research does and doesn't show, as of October 2026.

BPC-157

What it is. A 15-amino-acid peptide ("body protection compound"). Reviews describe it as a gastric peptide; the products in circulation are synthetic [1, 2].

What the animal research shows. Many studies, mostly in rats and mice, report faster healing of tendon, ligament, muscle and bone injuries [1, 3]. These results are consistently positive. But they come largely from a small number of research groups, and as one review puts it, efficacy is "yet to be confirmed in humans" [3].

What the human research shows. Very little:

  • A 2025 systematic review found 36 relevant studies: 35 preclinical and one clinical [1]. That clinical study was a retrospective chart review at one clinic [4]. Patients were contacted by phone months after a knee injection. Of 16, 14 said their knee pain had improved (11 of the 12 who had BPC-157 alone). There was no comparison group, and no validated measures of pain or function [4, 5].
  • A 2026 systematic review of human studies only found three studies with 30 participants in total, all of poor methodological quality. It rated the overall certainty of evidence as very low, and concluded that BPC-157 should not be used clinically outside ethically approved, high-quality trials [2].
  • A 2026 review for orthopaedic surgeons reached the same conclusion: routine clinical use can't currently be recommended [5].

Safety. No clinical safety data exist in humans; animal studies reported no adverse effects [1]. Reviewers also flag product quality: identity, purity, concentration, sterility and consistency of commercial products are unverified [5].

Status:

  • FDA: not approved. On its page about bulk substances for drug compounding, FDA lists BPC-157 among substances nominated and later withdrawn. It notes possible immunogenicity for some routes of use, and says it "lacks sufficient information to know whether the drug would cause harm when administered to humans" [6].
  • Sport: prohibited at all times by the World Anti-Doping Agency (class S0, non-approved substances), which names BPC-157 explicitly [7].

TB-500

What it is, and what it isn't. TB-500 is often described as thymosin beta-4 (Tβ4), a natural 43-amino-acid protein. It isn't the same thing. Analysis of a product sold as TB-500 identified a short, 7-amino-acid fragment of Tβ4 [8]. A 2026 review notes the two are frequently conflated "despite the absence of validated biologic or clinical equivalence" [5].

What the human research shows:

  • For TB-500 itself: none that we found. FDA states it has not identified any human exposure data for drug products containing the Tβ4 fragment [6].
  • For full-length Tβ4: a few early human studies exist, but not for muscles or tendons. They include a safety study of intravenous Tβ4 in healthy volunteers [9], and a small trial of Tβ4 eye drops in nine people with severe dry eye, which improved signs and symptoms compared with placebo drops [10].
  • For musculoskeletal use: the evidence is limited to lab and rodent studies [5].

Status:

  • FDA: not approved, and listed among compounding substances nominated and later withdrawn, citing possible immunogenicity and a lack of safety information [6].
  • Sport: prohibited by the World Anti-Doping Agency at all times under class S2 (peptide hormones and growth factors), as "Thymosin-β4 and its derivatives e.g. TB-500" [7].

The bottom line

  • Both compounds have interesting animal research and almost no human evidence for injury recovery.
  • Neither is approved for human use, neither has human safety data for the way it's commonly used, and both are banned in sport.
  • If you're dealing with an injury, a sports-medicine clinician or physiotherapist is the place to start.

What the research does support for recovering from a soft-tissue injury is less exotic, and it comes from human trials:

  • eating enough, including enough protein, while you're less active;
  • progressive rehabilitation exercise.

That's covered in a separate article.

References

  1. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551
  2. Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). doi:10.52628/92.3.15837
  3. Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377:153-159. doi:10.1007/s00441-019-03016-8
  4. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
  5. Tham A, et al. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg. 2026. doi:10.5435/JAAOS-D-26-00049
  6. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  7. World Anti-Doping Agency. The Prohibited List (2026 List; class S0, non-approved substances, and class S2.3, growth factors). https://www.wada-ama.org/en/prohibited-list (accessed 27 October 2026)
  8. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4:733-738. doi:10.1002/dta.1402
  9. Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25:8222-8228. doi:10.1111/jcmm.16693
  10. Sosne G, et al. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015. doi:10.1097/ICO.0000000000000379

This is a summary of other people's research; it isn't our study, and no Supptide product was studied in it. Educational; not medical advice.